A low headline price does not tell you whether a provider can safely prescribe. To understand Orlistat eligibility rules, start with this distinction: an online form can begin an assessment, but only a suitably qualified UK prescriber can decide whether treatment is appropriate after reviewing your information.
Orlistat is a prescription medicine used as part of weight-management care. It works in the gut by reducing the absorption of some dietary fat. That mechanism explains both the eligibility checks and the practical commitments attached to treatment. It is not a shortcut, and a BMI figure alone is not an automatic approval.
The starting point: BMI and weight-related health risks
For licensed prescription use in the UK, Orlistat is generally considered for adults with a body mass index (BMI) of 30 or above. It may also be considered from a BMI of 28 where there are weight-related risk factors, such as type 2 diabetes, high blood pressure or abnormal blood fats.
These thresholds are a starting point, not a guarantee. Providers may set their own clinical acceptance criteria within the medicine’s licence and their prescribers’ professional judgement. Some will ask for more detail about medical history, current measurements, lifestyle support and previous attempts to manage weight before reaching a decision.
BMI is a screening tool rather than a complete picture of health. A clinician may consider factors that BMI does not capture well, including body composition, ethnicity-related health risk, relevant medical history and medicines already being taken. That is why a provider that promises approval based on one number should raise questions.
Understand Orlistat eligibility rules beyond BMI
The prescriber’s job is not simply to verify height and weight. They need to establish whether Orlistat can be used safely, whether it fits the stated treatment goal and whether another route is more suitable. An appropriate online assessment should ask clear questions and leave room for follow-up where answers need clarification.
Medical history and conditions that may rule it out
Orlistat is not suitable for everyone. It is generally avoided in pregnancy and while breastfeeding. Certain digestive and liver-related conditions can also make it unsuitable, including chronic malabsorption syndrome and cholestasis, where the flow of bile from the liver is reduced or blocked.
A prescriber may also need to explore a history of eating disorders, pancreatic conditions, kidney problems or previous gastrointestinal surgery. This does not mean every disclosed condition leads to refusal. It means the clinician needs enough information to make a safe decision rather than treating the questionnaire as a box-ticking exercise.
Be wary of services that barely ask about health history, or encourage users to select answers that will produce an approval. Accurate answers protect the person being assessed and help avoid unsuitable prescribing.
Current medicines and interaction checks
Medication checks matter particularly with Orlistat because reducing fat absorption can affect how some treatments work or are managed. A prescriber may need to review medicines such as ciclosporin, anticoagulants including warfarin, levothyroxine and some treatments for epilepsy or HIV.
This is not a complete interaction list, and it should not be used to self-screen. The key consumer question is simpler: does the provider ask for all prescription medicines, over-the-counter products and supplements, then explain what happens if an interaction needs reviewing? If the form does not do this, the low price is not the main problem.
Diet, side effects and ability to use treatment safely
Because Orlistat affects dietary fat absorption, its gastrointestinal side effects can be more noticeable when meals are higher in fat. A clinician should make sure the person being assessed understands this practical point and the role of a nutritionally balanced, reduced-calorie eating plan.
Reduced absorption may also affect fat-soluble vitamins. Providers vary in the advice and follow-up they include, but they should not present the medicine as requiring no dietary consideration or clinical review. Good care is not just a parcel arriving at the door.
Private-provider rules can be stricter than the licence
The medicine’s licensed criteria and a provider’s eligibility policy are not identical things. A provider may decline to prescribe where information is incomplete, measurements appear unreliable, a medical condition needs in-person review or treatment is not considered clinically appropriate. It may also pause an application and ask for evidence from a GP or another clinician.
That can feel frustrating when someone has already paid for an assessment. It is still preferable to a provider that treats every order as a transaction. Before paying, read the provider’s terms on assessment fees, refusal outcomes, refunds and what happens when further information is requested.
A few policies deserve close attention:
- Is the initial clinical assessment included in the advertised medicine price, or charged separately?
- If a prescriber decides not to prescribe, is any payment refunded, credited or retained as an assessment fee?
- Does the displayed price include dispensing, delivery and required follow-up reviews?
- Is there a recurring subscription, minimum commitment or notice period for cancellation?
These are commercial questions, but they matter to safe access. A cheap first-month offer can become expensive if consultation charges, delivery costs or mandatory subscriptions are shown only later in the journey.
What a legitimate online assessment should look like
A private online pathway can be appropriate when it is properly run. It should identify the prescribing service, explain who will make the clinical decision and name the pharmacy that will dispense the medicine. The clinician may contact the applicant for clarification, request supporting information or decide that an online route is not suitable.
Never use a provider that cannot clearly confirm its prescriber credentials, pharmacy arrangements and relevant regulatory status. In the UK, doctors can be checked against the GMC register, while other qualified prescribers have their own professional registers. A dispensing pharmacy should be properly registered, and the service should be open about how to raise a complaint.
It is also worth checking whether the provider offers meaningful follow-up rather than only automated reorder prompts. Follow-up is where concerns about side effects, tolerability, changes in health or the suitability of continuing treatment can be raised with a clinician.
Approval is not the only outcome worth planning for
People often compare providers as though the only possible result is an approved prescription. In reality, a responsible assessment can lead to approval, a request for more information, a recommendation to speak with a GP or another clinician, or a decision not to prescribe.
None of those outcomes should be framed as a failure. The value of a clinical assessment is that it tests suitability before medicine is supplied. A service that guarantees approval removes the very safeguard that makes prescription treatment different from ordinary online shopping.
When comparing options, separate the questions. First, can the provider clearly explain its eligibility policy and clinical process? Second, can it show the full ongoing cost, including any consultations, dispensing, delivery and subscription conditions? Finally, can it demonstrate that a UK-registered clinician will make the decision after assessment?
PickMyClinic compares provider-set information to make those questions easier to ask, but comparison is not a prescription decision. Prices and policies can change, and the clinician reviewing an individual assessment has the final say.
The sensible next step is not to hunt for the easiest approval. It is to choose a provider whose eligibility checks, clinical oversight and total costs are clear before you begin the assessment.